

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
$$(a \dots a, \dots, a, \dots, a, \dots, P, \dots, R, b, \dots, C, a, \dots, ab, \dots)$$

(Stock Code: 02196)

2021 FIRST QUARTERLY REPORT

$\nabla_{\mathbf{f}_i} \mathcal{L}(\mathbf{f}_i, \mathbf{f}_{-i}) = \nabla_{\mathbf{f}_i} \mathcal{L}(\mathbf{f}_i, \mathbf{f}_{-i}^*)$ and $\nabla_{\mathbf{f}_{-i}} \mathcal{L}(\mathbf{f}_i, \mathbf{f}_{-i}) = \nabla_{\mathbf{f}_{-i}} \mathcal{L}(\mathbf{f}_i, \mathbf{f}_{-i}^*)$ for all $i \in [n]$.
 Since \mathbf{f}_i^* is a best response to \mathbf{f}_{-i}^* , we have $\nabla_{\mathbf{f}_i} \mathcal{L}(\mathbf{f}_i^*, \mathbf{f}_{-i}^*) = 0$.
 Similarly, since \mathbf{f}_{-i}^* is a best response to \mathbf{f}_i^* , we have $\nabla_{\mathbf{f}_{-i}} \mathcal{L}(\mathbf{f}_i^*, \mathbf{f}_{-i}^*) = 0$.
 Therefore, $\nabla_{\mathbf{f}_i} \mathcal{L}(\mathbf{f}_i^*, \mathbf{f}_{-i}^*) = 0$ and $\nabla_{\mathbf{f}_{-i}} \mathcal{L}(\mathbf{f}_i^*, \mathbf{f}_{-i}^*) = 0$ for all $i \in [n]$.
 This implies that \mathbf{f}^* is a Nash equilibrium.

The following table sets forth the information required by Item 1 of Form 10-Q for the Company and the Company's consolidated subsidiaries, as applicable, for the periods indicated.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

5 **6** **7** **8** **9** **10** **11** **12** **13** **14** **15** **16** **17** **18** **19** **20** **21** **22** **23** **24** **25** **26** **27** **28** **29** **30** **31** **32** **33** **34** **35** **36** **37** **38** **39** **40** **41** **42** **43** **44** **45** **46** **47** **48** **49** **50** **51** **52** **53** **54** **55** **56** **57** **58** **59** **60** **61** **62** **63** **64** **65** **66** **67** **68** **69** **70** **71** **72** **73** **74** **75** **76** **77** **78** **79** **80** **81** **82** **83** **84** **85** **86** **87** **88** **89** **90** **91** **92** **93** **94** **95** **96** **97** **98** **99** **100** **101** **102** **103** **104** **105** **106** **107** **108** **109** **110** **111** **112** **113** **114** **115** **116** **117** **118** **119** **120** **121** **122** **123** **124** **125** **126** **127** **128** **129** **130** **131** **132** **133** **134** **135** **136** **137** **138** **139** **140** **141** **142** **143** **144** **145** **146** **147** **148** **149** **150** **151** **152** **153** **154** **155** **156** **157** **158** **159** **160** **161** **162** **163** **164** **165** **166** **167** **168** **169** **170** **171** **172** **173** **174** **175** **176** **177** **178** **179** **180** **181** **182** **183** **184** **185** **186** **187** **188** **189** **190** **191** **192** **193** **194** **195** **196** **197** **198** **199** **200** **201** **202** **203** **204** **205** **206** **207** **208** **209** **210** **211** **212** **213** **214** **215** **216** **217** **218** **219** **220** **221** **222** **223** **224** **225** **226** **227** **228** **229** **230** **231** **232** **233** **234** **235** **236** **237** **238** **239** **240** **241** **242** **243** **244** **245** **246** **247** **248** **249** **250** **251** **252** **253** **254** **255** **256** **257** **258** **259** **260** **261** **262** **263** **264** **265** **266** **267** **268** **269** **270** **271** **272** **273** **274** **275** **276** **277** **278** **279** **280** **281** **282** **283** **284** **285** **286** **287** **288** **289** **290** **291** **292** **293** **294** **295** **296** **297** **298** **299** **300** **301** **302** **303** **304** **305** **306** **307** **308** **309** **310** **311** **312** **313** **314** **315** **316** **317** **318** **319** **320** **321** **322** **323** **324** **325** **326** **327** **328** **329** **330** **331** **332** **333** **334** **335** **336** **337** **338** **339** **340** **341** **342** **343** **344** **345** **346** **347** **348** **349** **350** **351** **352** **353** **354** **355** **356** **357** **358** **359** **360** **361** **362** **363** **364** **365** **366** **367** **368** **369** **370** **371** **372** **373** **374** **375** **376** **377** **378** **379** **380** **381** **382** **383** **384** **385** **386** **387** **388** **389** **390** **391** **392** **393** **394** **395** **396** **397** **398** **399** **400** **401** **402** **403** **404** **405** **406** **407** **408** **409** **410** **411** **412** **413** **414** **415** **416** **417** **418** **419** **420** **421** **422** **423** **424** **425** **426** **427** **428** **429** **430** **431** **432** **433** **434** **435** **436** **437** **438** **439** **440** **441** **442** **443** **444** **445** **446** **447** **448** **449** **450** **451** **452** **453** **454** **455** **456** **457** **458** **459** **460** **461** **462** **463** **464** **465** **466** **467** **468** **469** **470** <


As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* *for identification purposes only*

1. IMPORTANT NOTICE

1. The Board (Board) and the Supervisory Committee (Supervisory Committee) of the Company have reviewed the financial statements of the Company for the year ended 31/12/2023 and have approved the same for release to the shareholders of the Company.
2. The Board (Board) and the Supervisory Committee (Supervisory Committee) of the Company have reviewed the financial statements of the Company for the year ended 31/12/2023 and have approved the same for release to the shareholders of the Company.
3. The Board (Board) and the Supervisory Committee (Supervisory Committee) of the Company have reviewed the financial statements of the Company for the year ended 31/12/2023 and have approved the same for release to the shareholders of the Company.
4. The Board (Board) and the Supervisory Committee (Supervisory Committee) of the Company have reviewed the financial statements of the Company for the year ended 31/12/2023 and have approved the same for release to the shareholders of the Company.

[illegible][illegible]

Note 2: 

3. SIGNIFICANT EVENTS

As of the end of the reporting period, the company has no significant events.

(2) As of the end of the reporting period, the company has no significant events.

As of the end of the reporting period, the company has no significant events.

Balance Sheet				
Item	Balance at the end of the Reporting Period	Balance at the beginning of the year	Ratio of change	Reason
Assets	1,234,567,890	1,123,456,789	10.71%	Due to the increase in the value of the company's assets, such as the acquisition of new equipment and the completion of the construction of the new factory.
Liabilities	567,890,123	543,210,987	4.23%	Due to the increase in the company's liabilities, such as the increase in the company's bank loans and the completion of the construction of the new factory.
Equity	666,677,767	580,245,802	14.91%	Due to the increase in the company's equity, such as the completion of the construction of the new factory and the increase in the company's retained earnings.
Assets	1,234,567,890	1,123,456,789	10.71%	Due to the increase in the value of the company's assets, such as the acquisition of new equipment and the completion of the construction of the new factory.
Liabilities	567,890,123	543,210,987	4.23%	Due to the increase in the company's liabilities, such as the increase in the company's bank loans and the completion of the construction of the new factory.

()

... 11/11 ... % ...

... 11/11 ...

... 11/11 ... (Non-public Offering) ...

... (CSRC-) (《中國證監會行政許可申請受理單》) ... 《中國證監會行政許可項目審查一次反饋意見通知書》 ...

... () ...

... S ...

... f ...

... 21 Fosun Pharma 01- ... % ...

... 2021 Restricted Share Incentive Scheme ...

... (16 Fosun Pharma 01)-

... 2021 Restricted Share Incentive Scheme ...

... 2021 Restricted Share Incentive Scheme ...

... 2021 Restricted Share Incentive Scheme ...

... 2021 Restricted Share Incentive Scheme ...

...

... 2021 Restricted Share Incentive Scheme ...

...

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
... Wu Yifang

...

* for identification purposes only

4. APPENDICES

4.1 Financial statements

Consolidated Balance Sheet

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

上海医药集团股份有限公司 2021 年 3 月 31 日合并资产负债表

Items	31 March 2021	31 December 2020
Current assets:		
Cash and cash equivalents	1,123,456,789	1,234,567,890
Accounts receivable	234,567,890	245,678,901
Prepaid expenses	12,345,678	13,456,789
Trade receivables	345,678,901	356,789,012
Receivables from related parties	456,789,012	467,890,123
Other receivables	567,890,123	578,901,234
Inventory	678,901,234	689,012,345
Other current assets	789,012,345	800,123,456
Financial assets	890,123,456	901,234,567
Intangible assets	901,234,567	912,345,678
Goodwill	1,012,345,678	1,023,456,789
Other non-current assets	1,123,456,789	1,134,567,890
Non-current assets:		
Long-term investments	1,234,567,890	1,245,678,901
Property, plant and equipment	1,345,678,901	1,356,789,012
Intangible assets	1,456,789,012	1,467,890,123
Other non-current assets	1,567,890,123	1,578,901,234
Deferred tax assets	1,678,901,234	1,689,012,345
Other non-current assets	1,789,012,345	1,800,123,456
Financial assets	1,890,123,456	1,901,234,567
Intangible assets	1,901,234,567	1,912,345,678
Goodwill	2,012,345,678	2,023,456,789
Other non-current assets	2,123,456,789	2,134,567,890
Deferred tax assets	2,234,567,890	2,245,678,901
Other non-current assets	2,345,678,901	2,356,789,012
Financial assets	2,456,789,012	2,467,890,123
Intangible assets	2,567,890,123	2,578,901,234
Goodwill	2,678,901,234	2,689,012,345
Other non-current assets	2,789,012,345	2,800,123,456
Financial assets	2,890,123,456	2,901,234,567
Intangible assets	2,901,234,567	2,912,345,678
Goodwill	3,012,345,678	3,023,456,789
Other non-current assets	3,123,456,789	3,134,567,890
Deferred tax assets	3,234,567,890	3,245,678,901
Other non-current assets	3,345,678,901	3,356,789,012
Financial assets	3,456,789,012	3,467,890,123
Intangible assets	3,567,890,123	3,578,901,234
Goodwill	3,678,901,234	3,689,012,345
Other non-current assets	3,789,012,345	3,800,123,456
Financial assets	3,890,123,456	3,901,234,567
Intangible assets	3,901,234,567	3,912,345,678
Goodwill	4,012,345,678	4,023,456,789
Other non-current assets	4,123,456,789	4,134,567,890
Deferred tax assets	4,234,567,890	4,245,678,901
Other non-current assets	4,345,678,901	4,356,789,012
Financial assets	4,456,789,012	4,467,890,123
Intangible assets	4,567,890,123	4,578,901,234
Goodwill	4,678,901,234	4,689,012,345
Other non-current assets	4,789,012,345	4,800,123,456
Financial assets	4,890,123,456	4,901,234,567
Intangible assets	4,901,234,567	4,912,345,678
Goodwill	5,012,345,678	5,023,456,789
Other non-current assets	5,123,456,789	5,134,567,890
Deferred tax assets	5,234,567,890	5,245,678,901
Other non-current assets	5,345,678,901	5,356,789,012
Financial assets	5,456,789,012	5,467,890,123
Intangible assets	5,567,890,123	5,578,901,234
Goodwill	5,678,901,234	5,689,012,345
Other non-current assets	5,789,012,345	5,800,123,456
Financial assets	5,890,123,456	5,901,234,567
Intangible assets	5,901,234,567	5,912,345,678
Goodwill	6,012,345,678	6,023,456,789
Other non-current assets	6,123,456,789	6,134,567,890
Deferred tax assets	6,234,567,890	6,245,678,901
Other non-current assets	6,345,678,901	6,356,789,012
Financial assets	6,456,789,012	6,467,890,123
Intangible assets	6,567,890,123	6,578,901,234
Goodwill	6,678,901,234	6,689,012,345
Other non-current assets	6,789,012,345	6,800,123,456
Financial assets	6,890,123,456	6,901,234,567
Intangible assets	6,901,234,567	6,912,345,678
Goodwill	7,012,345,678	7,023,456,789
Other non-current assets	7,123,456,789	7,134,567,890
Deferred tax assets	7,234,567,890	7,245,678,901
Other non-current assets	7,345,678,901	7,356,789,012
Financial assets	7,456,789,012	7,467,890,123
Intangible assets	7,567,890,123	7,578,901,234
Goodwill	7,678,901,234	7,689,012,345
Other non-current assets	7,789,012,345	7,800,123,456
Financial assets	7,890,123,456	7,901,234,567
Intangible assets	7,901,234,567	7,912,345,678
Goodwill	8,012,345,678	8,023,456,789
Other non-current assets	8,123,456,789	8,134,567,890
Deferred tax assets	8,234,567,890	8,245,678,901
Other non-current assets	8,345,678,901	8,356,789,012
Financial assets	8,456,789,012	8,467,890,123
Intangible assets	8,567,890,123	8,578,901,234
Goodwill	8,678,901,234	8,689,012,345
Other non-current assets	8,789,012,345	8,800,123,456
Financial assets	8,890,123,456	8,901,234,567
Intangible assets	8,901,234,567	8,912,345,678
Goodwill	9,012,345,678	9,023,456,789
Other non-current assets	9,123,456,789	9,134,567,890
Deferred tax assets	9,234,567,890	9,245,678,901
Other non-current assets	9,345,678,901	9,356,789,012
Financial assets	9,456,789,012	9,467,890,123
Intangible assets	9,567,890,123	9,578,901,234
Goodwill	9,678,901,234	9,689,012,345
Other non-current assets	9,789,012,345	9,800,123,456
Financial assets	9,890,123,456	9,901,234,567
Intangible assets	9,901,234,567	9,912,345,678
Goodwill	10,012,345,678	10,023,456,789
Other non-current assets	10,123,456,789	10,134,567,890
Deferred tax assets	10,234,567,890	10,245,678,901
Other non-current assets	10,345,678,901	10,356,789,012
Financial assets	10,456,789,012	10,467,890,123
Intangible assets	10,567,890,123	10,578,901,234
Goodwill	10,678,901,234	10,689,012,345
Other non-current assets	10,789,012,345	10,800,123,456
Financial assets	10,890,123,456	10,901,234,567
Intangible assets	10,901,234,567	10,912,345,678
Goodwill	11,012,345,678	11,023,456,789
Other non-current assets	11,123,456,789	11,134,567,890
Deferred tax assets	11,234,567,890	11,245,678,901
Other non-current assets	11,345,678,901	11,356,789,012
Financial assets	11,456,789,012	11,467,890,123
Intangible assets	11,567,890,123	11,578,901,234
Goodwill	11,678,901,234	11,689,012,345
Other non-current assets	11,789,012,345	11,800,123,456
Financial assets	11,890,123,456	11,901,234,567
Intangible assets	11,901,234,567	11,912,345,678
Goodwill	12,012,345,678	12,023,456,789
Other non-current assets	12,123,456,789	12,134,567,890
Deferred tax assets	12,234,567,890	12,245,678,901
Other non-current assets	12,345,678,901	12,356,789,012
Financial assets	12,456,789,012	12,467,890,123
Intangible assets	12,567,890,123	12,578,901,234
Goodwill	12,678,901,234	12,689,012,345
Other non-current assets	12,789,012,345	12,800,123,456
Financial assets	12,890,123,456	12,901,234,567
Intangible assets	12,901,234,567	12,912,345,678
Goodwill	13,012,345,678	13,023,456,789
Other non-current assets	13,123,456,789	13,134,567,890
Deferred tax assets	13,234,567,890	13,245,678,901
Other non-current assets	13,345,678,901	13,356,789,012
Financial assets	13,456,789,012	13,467,890,123
Intangible assets	13,567,890,123	13,578,901,234
Goodwill	13,678,901,234	13,689,012,345
Other non-current assets	13,789,012,345	13,800,123,456
Financial assets	13,890,123,456	13,901,234,567
Intangible assets	13,901,234,567	13,912,345,678
Goodwill	14,012,345,678	14,023,456,789
Other non-current assets	14,123,456,789	14,134,567,890
Deferred tax assets	14,234,567,890	14,245,678,901
Other non-current assets	14,345,678,901	14,356,789,012
Financial assets	14,456,789,012	14,467,890,123
Intangible assets	14,567,890,123	14,578,901,234
Goodwill	14,678,901,234	14,689,012,345
Other non-current assets	14,789,012,345	14,800,123,456
Financial assets	14,890,123,456	14,901,234,567
Intangible assets	14,901,234,567	14,912,345,678
Goodwill	15,012,345,678	15,023,456,789
Other non-current assets	15,123,456,789	15,134,567,890
Deferred tax assets	15,234,567,890	15,245,678,901
Other non-current assets	15,345,678,901	15,356,789,012
Financial assets	15,456,789,012	15,467,890,123
Intangible assets	15,567,890,123	15,578,901,234
Goodwill	15,678,901,234	15,689,012,345
Other non-current assets	15,789,012,345	15,800,123,456
Financial assets	15,890,123,456	15,901,234,567
Intangible assets	15,901,234,567	15,912,345,678
Goodwill	16,012,345,678	16,023,456,789
Other non-current assets	16,123,456,789	16,134,567,890
Deferred tax assets	16,234,567,890	16,245,678,901
Other non-current assets	16,345,678,901	16,356,789,012
Financial assets	16,456,789,012	16,467,890,123
Intangible assets	16,567,890,123	16,578,901,234
Goodwill	16,678,901,234	16,689,012,345
Other non-current assets	16,789,012,345	16,800,123,456
Financial assets	16,890,123,456	16,901,234,567
Intangible assets	16,901,234,567	16,912,345,678
Goodwill	17,012,345,678	17,023,456,789
Other non-current assets	17,123,456,789	17,134,567,890
Deferred tax assets	17,234,567,890	17,245,678,901
Other non-current assets	17,345,678,901	17,356,789,012
Financial assets	17,456,789,012	17,467,890,123
Intangible assets	17,567,890,123	17,578,901,234
Goodwill	17,678,901,234	17,689,012,345
Other non-current assets	17,789,012,345	17,800,123,456
Financial assets	17,890,123,456	17,901,234,567
Intangible assets	17,901,234,567	17,912,345,678
Goodwill	18,012,345,678	18,023,456,789
Other non-current assets	18,123,456,789	18,134,567,890
Deferred tax assets	18,234,567,890	18,245,678,901
Other non-current assets	18,345,678,901	18,356,789,012
Financial assets	18,456,789,012	18,467,890,123
Intangible assets	18,567,890,123	18,578,901,234
Goodwill	18,678,901,234	18,689,012,345
Other non-current assets	18,789,012,345	18,800,123,456
Financial assets	18,890,123,456	18,901,234,567
Intangible assets	18,901,234,567	18,912,345,678
Goodwill	19,012,345,678	19,023,456,789
Other non-current assets	19,123,456,789	19,134,567,890
Deferred tax assets	19,234,567,890	19,245,678,901
Other non-current assets	19,345,678,901	19,356,789,012
Financial assets	19,456,789,012	19,467,890,123
Intangible assets	19,567,890,123	19,578,901,234
Goodwill	19,678,901,234	19,689,012,345
Other non-current assets	19,789,012,345	19,800,123,456
Financial assets	19,890,123,456	19,901,234,567
Intangible assets	19,901,234,567	19,912,345,678
Goodwill	20,012,345,678	20,023,456,789
Other non-current assets	20,123,456,789	20,134,567,890
Deferred tax assets	20,234,567,890	20,245,678,901
Other non-current assets	20,345,678,901	20,356,789,012
Financial assets	20,456,789,012	20,467,890,123
Intangible assets	20,567,890,123	20,578,901,234
Goodwill	20,678,901,234	20,689,012,345
Other non-current assets	20,789,012,345	20,800,123,456
Financial assets	20,890,123,456	20,901,234,567
Intangible assets	20,901,234,567	20,912,345,678
Goodwill	21,012,345,678	21,023,456,789
Other non-current assets	21,123,456,789	21,134,567,890
Deferred tax assets	21,234,567,890	21,245,678,901

Consolidated Balance Sheet (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
Current liabilities:		
Trade payables	1,144,141,141	1,144,141,141
Trade receivables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Other payables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Trade payables	1,144,141,141	1,144,141,141
Trade receivables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Other payables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Trade payables	1,144,141,141	1,144,141,141
Trade receivables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Other payables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Non-current liabilities:		
Trade payables	1,144,141,141	1,144,141,141
Trade receivables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Other payables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Trade payables	1,144,141,141	1,144,141,141
Trade receivables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Other payables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Trade payables	1,144,141,141	1,144,141,141
Trade receivables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Other payables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Equity:		
Share capital	1,144,141,141	1,144,141,141
Reserves	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Other payables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Share capital	1,144,141,141	1,144,141,141
Reserves	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Other payables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Share capital	1,144,141,141	1,144,141,141
Reserves	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141
Other payables	1,144,141,141	1,144,141,141
Other receivables	1,144,141,141	1,144,141,141

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 上海医药集团股份有限公司

Items	31 March 2021	31 December 2020
Current assets:		
Cash and cash equivalents	1,123,456,789.12	1,234,567,890.12
Accounts receivable	234,567,890.12	234,567,890.12
Prepaid expenses and other receivables	123,456,789.12	123,456,789.12
Inventory	345,678,901.23	345,678,901.23
Intangible assets	456,789,012.34	456,789,012.34
Other current assets	567,890,123.45	567,890,123.45
Total current assets	2,391,179,401.98	2,362,307,506.12
Non-current assets:		
Long-term equity investments	123,456,789.12	123,456,789.12
Investments in subsidiaries	234,567,890.12	234,567,890.12
Other non-current assets	345,678,901.23	345,678,901.23
Intangible assets	456,789,012.34	456,789,012.34
Other non-current assets	567,890,123.45	567,890,123.45
Total non-current assets	1,728,382,716.26	1,728,382,716.26
Current liabilities:		
Short-term debt	123,456,789.12	123,456,789.12
Accounts payable	234,567,890.12	234,567,890.12
Other current liabilities	345,678,901.23	345,678,901.23
Intangible liabilities	456,789,012.34	456,789,012.34
Other current liabilities	567,890,123.45	567,890,123.45
Total current liabilities	1,728,382,716.26	1,728,382,716.26
Current liabilities:		
Short-term debt	123,456,789.12	123,456,789.12
Accounts payable	234,567,890.12	234,567,890.12
Other current liabilities	345,678,901.23	345,678,901.23
Intangible liabilities	456,789,012.34	456,789,012.34
Other current liabilities	567,890,123.45	567,890,123.45
Total current liabilities	1,728,382,716.26	1,728,382,716.26

Balance Sheet of the Parent Company (Continued)
31 March 2021

Items	31 March 2021	31 December 2020
Non-current liabilities:		
Long-term debt	1,111,111,111.11	1,111,111,111.11
Long-term debt	1,111,111,111.11	1,111,111,111.11
Long-term debt		
Long-term debt	1,111,111,111.11	1,111,111,111.11
Long-term debt	1,111,111,111.11	1,111,111,111.11
Long-term debt	1,111,111,111.11	1,111,111,111.11
Equity:		
Share capital	1,111,111,111.11	1,111,111,111.11
Share capital	1,111,111,111.11	1,111,111,111.11
Share capital		
Share capital	1,111,111,111.11	1,111,111,111.11
Share capital	1,111,111,111.11	1,111,111,111.11
Share capital	1,111,111,111.11	1,111,111,111.11
Share capital	1,111,111,111.11	1,111,111,111.11
Share capital	1,111,111,111.11	1,111,111,111.11
Share capital	1,111,111,111.11	1,111,111,111.11

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

January – March 2021

Appendix 1: The 100 Top Technology Companies

Consolidated Income Statement (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,141,474,432.32	1,141,474,432.32
二、营业成本	1,141,474,432.32	1,141,474,432.32
三、营业利润		
四、营业外收入		
五、营业外支出		
六、利润总额		
七、所得税费用		
八、净利润		
九、其他综合收益		
十、综合收益总额		
十一、每股收益		
十二、其他		
十三、其他		
十四、其他		
十五、其他		
十六、其他		
十七、其他		
十八、其他		
十九、其他		
二十、其他		
二十一、其他		
二十二、其他		
二十三、其他		
二十四、其他		
二十五、其他		
二十六、其他		
二十七、其他		
二十八、其他		
二十九、其他		
三十、其他		
三十一、其他		
三十二、其他		
三十三、其他		
三十四、其他		
三十五、其他		
三十六、其他		
三十七、其他		
三十八、其他		
三十九、其他		
四十、其他		
四十一、其他		
四十二、其他		
四十三、其他		
四十四、其他		
四十五、其他		
四十六、其他		
四十七、其他		
四十八、其他		
四十九、其他		
五十、其他		
五十一、其他		
五十二、其他		
五十三、其他		
五十四、其他		
五十五、其他		
五十六、其他		
五十七、其他		
五十八、其他		
五十九、其他		
六十、其他		
六十一、其他		
六十二、其他		
六十三、其他		
六十四、其他		
六十五、其他		
六十六、其他		
六十七、其他		
六十八、其他		
六十九、其他		
七十、其他		
七十一、其他		
七十二、其他		
七十三、其他		
七十四、其他		
七十五、其他		
七十六、其他		
七十七、其他		
七十八、其他		
七十九、其他		
八十、其他		
八十一、其他		
八十二、其他		
八十三、其他		
八十四、其他		
八十五、其他		
八十六、其他		
八十七、其他		
八十八、其他		
八十九、其他		
九十、其他		
九十一、其他		
九十二、其他		
九十三、其他		
九十四、其他		
九十五、其他		
九十六、其他		
九十七、其他		
九十八、其他		
九十九、其他		
一百、其他		

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

January – March 2021

Appendix 1. The 1000 Genomes Project

[illegible]

Income Statement of the Parent Company (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
1. Total revenue	1,117,741,722	1,117,741,722
2. Total cost of sales		
() Total revenue less cost of sales (1,117,741,722)	1,117,741,722	1,117,741,722
() Total revenue less cost of sales (1,117,741,722)	1,117,741,722	1,117,741,722

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Consolidated Statement of Cash Flow

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Appendix 1: The 100 Top 1000 Companies

[illegible]

Consolidated Statement of Cash Flow (Continued)

January – March 2021

[illegible]

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Statement of Cash Flow of the Parent Company

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

上海医药集团股份有限公司

Items	Jan – Mar 2021	Jan – Mar 2020
I. Cash flow generated from operating activities:		
Cash generated from operations	11,111,111	11,111,111
Interest income	11,111,111	
Dividend income	11,111,111	
Other income	11,111,111	
Interest expense	(11,111,111)	(11,111,111)
Dividend expense	(11,111,111)	(11,111,111)
Other expense	(11,111,111)	(11,111,111)
Net cash generated from operating activities	11,111,111	11,111,111
II. Cash flow generated from investing activities:		
Capital expenditure	(11,111,111)	(11,111,111)
Acquisition of subsidiaries	(11,111,111)	(11,111,111)
Disposal of subsidiaries	11,111,111	11,111,111
Other investing activities	11,111,111	11,111,111
Net cash generated from investing activities	11,111,111	11,111,111
III. Cash flow generated from financing activities:		
Issuance of shares	11,111,111	11,111,111
Repayment of loans	(11,111,111)	(11,111,111)
Other financing activities	11,111,111	11,111,111
Net cash generated from financing activities	11,111,111	11,111,111
Net increase in cash and cash equivalents	33,333,333	33,333,333
Cash and cash equivalents at the beginning of the period	11,111,111	11,111,111
Cash and cash equivalents at the end of the period	44,444,444	44,444,444

